195 related articles for article (PubMed ID: 28263556)
1. A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.
Deibler KK; Mishra RK; Clutter MR; Antanasijevic A; Bergan R; Caffrey M; Scheidt KA
ACS Chem Biol; 2017 May; 12(5):1245-1256. PubMed ID: 28263556
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors.
Deibler KK; Schiltz GE; Clutter MR; Mishra RK; Vagadia PP; O'Connor M; George MD; Gordon R; Fowler G; Bergan R; Scheidt KA
ChemMedChem; 2019 Mar; 14(6):615-620. PubMed ID: 30707493
[TBL] [Abstract][Full Text] [Related]
3. Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Mishra RK; Deibler KK; Clutter MR; Vagadia PP; O'Connor M; Schiltz GE; Bergan R; Scheidt KA
J Chem Inf Model; 2019 Oct; 59(10):4460-4466. PubMed ID: 31566378
[TBL] [Abstract][Full Text] [Related]
4. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy.
Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL
Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470
[TBL] [Abstract][Full Text] [Related]
6. MEK4 function, genistein treatment, and invasion of human prostate cancer cells.
Xu L; Ding Y; Catalona WJ; Yang XJ; Anderson WF; Jovanovic B; Wellman K; Killmer J; Huang X; Scheidt KA; Montgomery RB; Bergan RC
J Natl Cancer Inst; 2009 Aug; 101(16):1141-55. PubMed ID: 19638505
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
9. Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma.
Kwong AJ; Pham TND; Oelschlager HE; Munshi HG; Scheidt KA
ACS Med Chem Lett; 2021 Oct; 12(10):1559-1567. PubMed ID: 34676038
[TBL] [Abstract][Full Text] [Related]
10. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H
Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324
[TBL] [Abstract][Full Text] [Related]
11. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
12. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
[TBL] [Abstract][Full Text] [Related]
13. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
[TBL] [Abstract][Full Text] [Related]
14. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
15. Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome.
Zhao Z; Xie L; Bourne PE
PLoS One; 2017; 12(6):e0179936. PubMed ID: 28628649
[TBL] [Abstract][Full Text] [Related]
16. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
[TBL] [Abstract][Full Text] [Related]
18. The small-molecule inhibitor selectivity between IKKα and IKKβ kinases in NF-κB signaling pathway.
Tian F; Zhou P; Kang W; Luo L; Fan X; Yan J; Liang H
J Recept Signal Transduct Res; 2015; 35(4):307-18. PubMed ID: 25386663
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents.
Singh VJ; Sharma B; Chawla PA
Bioorg Chem; 2021 Sep; 114():105161. PubMed ID: 34328852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
